São Paulo, Brazil – December 16, 2023 – A new dengue vaccine developed by teh Butantan Institute, a Brazilian public laboratory, demonstrates a meaningful ability to control dengue virus replication even in vaccinated individuals who become infected – known as vaccine escape cases. This breakthrough, detailed in a study published in The Lancet Regional Health-Americas, suggests the vaccine not only protects against severe disease but also potentially reduces the spread of the virus.
Vaccine Efficacy and Viral Load Reduction
The Butantan-DV vaccine has shown promising results in clinical trials. Data from Phase 3 trials, involving over 16,000 volunteers across 14 Brazilian states, indicate:
* Overall efficacy: 74.7%
* Efficacy against severe dengue: 91.6%
* Efficacy against hospitalization due to dengue: 100% https://www.butantan.gov.br/noticias/butantan-divulga-resultados-finais-do-estudo-da-vacina-contra-a-dengue/
Beyond these efficacy rates, the study highlights the vaccine’s ability to reduce the viral load in infected individuals. A lower viral load is associated with a decreased risk of transmission to mosquitoes, potentially contributing to a reduction in dengue outbreaks.
“This preliminary data suggests that vaccination can have an vital effect on the circulation of the virus, helping to minimize new outbreaks of the disease, but it is something that we still need to confirm with new studies,” explained Maurício Lacerda Nogueira, a professor at the Faculty of Medicine of São José do Rio Preto and author of the study.
Dengue in Brazil: A Public Health Challenge
Brazil faces a significant challenge with dengue fever, classified as a hyperendemic region with multiple dengue virus lineages circulating simultaneously. The approval of the Butantan-DV vaccine by the National Health Surveillance Agency (Anvisa) at the end of November 2023 https://www.gov.br/anvisa/pt-br/noticias/2023/11/anvisa-aprova-vacina-contra-dengue-produzida-pelo-butantan represents a major step forward in combating the disease.
The vaccine is slated to be included in brazil’s public health network beginning in 2026, initially targeting individuals between 12 and 59 years of age. esper Kallás, director of the Butantan Institute, oversaw the clinical trials of the vaccine, marking a significant achievement for the largest state vaccine manufacturing laboratory in Latin America.
Understanding Dengue and Vaccination
Dengue fever is a mosquito-borne viral infection that causes flu-like illness. Symptoms can range from mild to severe, and in some cases, can lead to life-threatening complications like dengue hemorrhagic fever. There are four distinct serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4).
Vaccination aims to stimulate the immune system to produce antibodies against the virus,providing protection against infection or reducing the severity of illness if infection occurs. The Butantan vaccine’s ability to reduce viral load even in breakthrough cases is a particularly encouraging finding, as it suggests a broader impact on disease transmission.
key Takeaways
* the Butantan Institute’s dengue vaccine demonstrates high efficacy against severe dengue and hospitalization.
* The vaccine reduces viral load in infected individuals, potentially limiting virus transmission.
* Brazil’s national vaccination program is expected to begin in 2026, targeting individuals aged 12-59.
* The vaccine represents a significant advancement in public health efforts to control dengue fever in Brazil and potentially other endemic regions.
Looking Ahead: Further research will be crucial to confirm the vaccine’s long-term impact on dengue transmission and to assess it’s effectiveness against different dengue virus serotypes circulating in Brazil and other regions. the Butantan Institute continues to monitor data and conduct studies to optimize the vaccine’s implementation and maximize its public health benefits.